Onco-Innovations Partners with Nucro-Technics for Preclinical Studies

Onco-Innovations Limited has signed an agreement with Nucro-Technics Inc. to conduct preclinical studies for its lead drug candidate. This move aims to support the development of Onco's PNKP inhibitor by assessing its safety and behavior in animal models. The studies will include drug metabolism testing and formal safety studies, critical for regulatory compliance. Nucro-Technics, known for its expertise in GLP-compliant testing, will handle the work.

The contract covers full IND-enabling work for Onco's lead program, NP/A83, targeting advanced-stage cancers. It will evaluate drug safety and the polymer delivery system, aiming to meet FDA and Health Canada standards. Results are expected to form the basis for an IND application and subsequent human trials. This agreement is pivotal for Onco's regulatory efforts and clinical development strategy.